This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Yuehong Liu
Tongren Hospital Shanghai Jiaotong University School of Medicine
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The main purpose of this study was to determine sVAP-1 levels in patients with moderate and severe obstructive sleep apnea (OSA) compared with healthy controls, and further determine the relationship between sVAP-1 concentration and biomarkers of vascular endothelial dysfunction (ED), including adropin and inflammatory factors.
Methods: In this study, we included 50 male patients with OSA (25 moderate and 25 severe) and 20 age- and sex-matched control subjects. The OSA patients underwent polysomnography and all subjects underwent fasting sampling of peripheral blood for laboratory analyses.
Results: Serum sVAP-1 levels and inflammatory biomarkers (IL-6, TNF-α, hsCRP) were significantly higher in patients with severe OSA in comparison with the moderate OSA and control groups, whereas plasma adropin levels presented a completely reverse trend. Moreover, sVAP-1 levels were in significant positive correlation with levels of AHI, ODI, TNF-α, IL-6 and hsCRP. However, it was significantly negative correlated with adropin levels. Receiver Operating Characteristic (ROC) analysis showed that AUC for sVAP-1levels in predicting OSA was 0.876 (P <.001,95% CI 0.784−0.968). Serum sVAP-1 cutoff value more than 445.5ng/mL provided 88% sensitivity and 80% specificity for the detection of OSA status. A multivariate regression analysis showed that sVAP-1 remained as a significant positive predictor of severe OSA status.
Conclusions: Serum sVAP-1 concentration significantly correlates with indices of OSA severity and biomarkers of ED, suggesting that sVAP-1 plays a vital role in the pathophysiology of ED-related diseases.
Keywords
sVAP-1, adropin, obstructive sleep apnea, endothelial dysfunction, biomarker
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 04 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Molecular Biology
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Yuehong Liu
Tongren Hospital Shanghai Jiaotong University School of Medicine
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 04 May, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Molecular Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: The main purpose of this study was to determine sVAP-1 levels in patients with moderate and severe obstructive sleep apnea (OSA) compared with healthy controls, and further determine the relationship between sVAP-1 concentration and biomarkers of vascular endothelial dysfunction (ED), including adropin and inflammatory factors.
Methods: In this study, we included 50 male patients with OSA (25 moderate and 25 severe) and 20 age- and sex-matched control subjects. The OSA patients underwent polysomnography and all subjects underwent fasting sampling of peripheral blood for laboratory analyses.
Results: Serum sVAP-1 levels and inflammatory biomarkers (IL-6, TNF-α, hsCRP) were significantly higher in patients with severe OSA in comparison with the moderate OSA and control groups, whereas plasma adropin levels presented a completely reverse trend. Moreover, sVAP-1 levels were in significant positive correlation with levels of AHI, ODI, TNF-α, IL-6 and hsCRP. However, it was significantly negative correlated with adropin levels. Receiver Operating Characteristic (ROC) analysis showed that AUC for sVAP-1levels in predicting OSA was 0.876 (P <.001,95% CI 0.784−0.968). Serum sVAP-1 cutoff value more than 445.5ng/mL provided 88% sensitivity and 80% specificity for the detection of OSA status. A multivariate regression analysis showed that sVAP-1 remained as a significant positive predictor of severe OSA status.
Conclusions: Serum sVAP-1 concentration significantly correlates with indices of OSA severity and biomarkers of ED, suggesting that sVAP-1 plays a vital role in the pathophysiology of ED-related diseases.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...